Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
731.77
-12.67 (-1.70%)
At close: Apr 28, 2026, 4:00 PM EDT
732.50
+0.73 (0.10%)
After-hours: Apr 28, 2026, 6:46 PM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
The 26 analysts with 12-month price forecasts for Regeneron Pharmaceuticals stock have an average target of 832.85, with a low estimate of 587 and a high estimate of 1,057. The average target predicts an increase of 13.81% from the current stock price of 731.77.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock from 26 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 9 | 10 |
| Buy | 8 | 7 | 8 | 7 | 9 | 9 |
| Hold | 6 | 7 | 7 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 25 | 23 | 25 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $880 → $960 | Strong Buy | Maintains | $880 → $960 | +31.19% | Apr 23, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $800 | Buy | Reiterates | $800 | +9.32% | Apr 23, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $769 → $796 | Hold | Maintains | $769 → $796 | +8.78% | Apr 10, 2026 |
| Bernstein | Bernstein | Buy Maintains $925 → $921 | Buy | Maintains | $925 → $921 | +25.86% | Apr 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $875 | Buy | Initiates | $875 | +19.57% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
16.13B
from 14.34B
Increased by 12.45%
Revenue Next Year
17.76B
from 16.13B
Increased by 10.13%
EPS This Year
46.88
from 41.48
Increased by 13.02%
EPS Next Year
55.16
from 46.88
Increased by 17.67%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 18.1B | 20.0B | ||||||
| Avg | 16.1B | 17.8B | ||||||
| Low | 14.4B | 15.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 26.0% | 23.9% | ||||||
| Avg | 12.4% | 10.1% | ||||||
| Low | 0.3% | -2.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 60.51 | 65.84 | ||||||
| Avg | 46.88 | 55.16 | ||||||
| Low | 36.39 | 45.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 45.9% | 40.4% | ||||||
| Avg | 13.0% | 17.7% | ||||||
| Low | -12.3% | -3.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.